Publications

  1. Menendez JA, Lupu R. Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targets. 2017 Sep 21; 1-16 Epub 2017 Sept 21
    View PubMed
  2. Corominas-Faja B, Vellon L, Cuyas E, Buxo M, Martin-Castillo B, Serra D, Garcia J, Lupu R, Menendez JA. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histol Histopathol. 2017 Jul; 32: (7)687-698.
    View PubMed
  3. Haddad T, Qin R, Lupu R, Satele D, Eadens M, Goetz MP, Erlichman C, Molina J. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017 Jun; 79: (6)1221-1227.
    View PubMed
  4. Cuyas E, Corominas-Faja B, Martin MM, Martin-Castillo B, Lupu R, Brunet J, Bosch-Barrera J, Menendez JA. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. Oncotarget. 2017 May 23; 8: (21)35019-35032.
    View PubMed
  5. Menendez JA, Lupu R. Fatty acid synthase regulates estrogen receptor-alpha signaling in breast cancer cells. Oncogenesis. 2017 Feb 27; 6 (2):e299
    View PubMed
  6. Colomer R, Sarrats A, Lupu R, Puig T. Natural polyphenols and their synthetic analogs as emerging anticancer agents Current Drug Targets. 2017; 18: (2)147-59.
  7. Gonzalez-Guerrico AM, Espinoza I, Schroeder B, Park CH, Kvp CM, Khurana A, Corominas-Faja B, Cuyas E, Alarcon T, Kleer C, Menendez JA, Lupu R. Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. Oncotarget. 2016 Nov 01; 7 (44):71151-71168
    View PubMed
  8. Cuyas E, Fernandez-Arroyo S, Alarcon T, Lupu R, Joven J, Menendez JA. Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers. Oncotarget. 2016 Aug 16; 7: (33)52974-52992.
    View PubMed
  9. Menendez JA, Vellon L, Espinoza I, Lupu R. The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells. Oncoscience. 2016; 3 (7-8):242-257 Epub 2016 July 22
    View PubMed
  10. Menendez JA, Rubio MA, Campisi J, Lupu R. Heregulin, a new regulator of telomere length in human cells. Oncotarget. 2015 Nov 24; 6: (37)39422-36.
    View PubMed
  11. Menendez JA, Benboudjema L, Vellon L, Rubio MA, Espinoza I, Campisi J, Lupu R. Heregulin, a new interactor of the telosomeshelterin complex in human telomeres. Oncotarget. 2015 Nov 24; 6: (37)39408-21.
    View PubMed
  12. Menendez JA, Schroeder B, Peirce SK, Vellon L, Papadimitropoulou A, Espinoza I, Lupu R. Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling. J Natl Cancer Inst. 2015 Jun; 107(6):djv090. Epub 2015 Apr 16.
    View PubMed
  13. Espinoza I, Menendez JA, Kvp CM, Lupu R. CCN1 promotes vascular endothelial growth factor secretion through alphavbeta 3 integrin receptors in breast cancer. J Cell Commun Signal. 2014 Mar; 8: (1)23-7.
    View PubMed
  14. Khurana A, Gonzalez-Guerrico A, Lupu R. Heregulin in breast cancer: old story, new paradigm. Curr Pharm Des. 2014; 20(30):4874-8.
    View PubMed
  15. Corominas-Faja B, Cufi S, Oliveras-Ferraros C, Cuyas E, Lopez-Bonet E, Lupu R, Alarcon T, Vellon L, Iglesias JM, Leis O, Martin AG, Vazquez-Martin A, Menendez JA. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle. 2013 Sep 15; 12(18):3109-24. Epub 2013 Aug 21.
    View PubMed
  16. Vazquez-Martin A, Corominas-Faja B, Cufi S, Vellon L, Oliveras-Ferraros C, Menendez OJ, Joven J, Lupu R, Menendez JA. The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells. Cell Cycle. 2013 Jan 15; 12(2):207-18. Epub 2012 Jan 15.
    View PubMed
  17. Espinoza I Menendez JA Chandra Mohan Kurapaty Venkatapoorna, Lupu R. CYR61 induces Vascular Endothelial Growth Factor (VEGF) secretion through αvβ3 integrin receptor in Breast Cancer. Journal of Cell Communication and Signaling. 2013.
  18. Lupu-Meiri M, Geras-Raaka E, Lupu R, Shapira H, Sandbank J, Segal L, Gershengorn MC, Oron Y. Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells. J Cell Physiol. 2012 Nov; 227(11):3621-8.
    View PubMed
  19. Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, Park JY, Harris CC, Yang P, Jen J. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 2012 Jul 01; 18: (13)3658-67.
    View PubMed
  20. Espinoza I, Liu H, Busby R, Lupu R. CCN1, a candidate target for zoledronic acid treatment in breast cancer. Mol Cancer Ther. 2011 May; 10: (5)732-41.
    View PubMed
  21. Eldar-Boock A, Miller K, Sanchis J, Lupu R, Vicent MJ, Satchi-Fainaro R. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials. 2011 May; 32(15):3862-74. Epub 2011 Mar 04.
    View PubMed
  22. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Addeo SR, Abbruzzese A, Budillon A, Caraglia M. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer. 2009 Nov 1; 125(9):2004-13.
    View PubMed
  23. Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun. 2009 Jul 31; 385(3):454-9. Epub 2009 May 23.
    View PubMed
  24. Deshet N, Lupu-Meiri M, Espinoza I, Fili O, Shapira Y, Lupu R, Gershengorn MC, Oron Y. Plasminogen-induced aggregation of PANC-1 cells requires conversion to plasmin and is inhibited by endogenous plasminogen activator inhibitor-1. J Cell Physiol. 2008 Sep; 216(3):632-9.
    View PubMed
  25. Lupu R, Colomer R, Menendez JA. An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value. Clin Transl Oncol. 2008 Apr; 10(4):219-26.
    View PubMed
  26. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 2008 Feb; 41(1):59-85.
    View PubMed
  27. Colomer R, Lupu R, Papadimitropoulou A, Vellon L, Vazquez-Martin A, Brunet J, Fernandez-Gutierrez A, Segura-Carretero A, Menendez JA. Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century? Clin Transl Oncol. 2008 Jan; 10(1):30-4.
    View PubMed
  28. Vellon L, Menendez JA, Liu H, Lupu R. Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner. Differentiation. 2007 Nov; 75(9):819-30.
    View PubMed
  29. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007 Oct; 7(10):763-77.
    View PubMed
  30. Menendez JA, Vellon V, Oza B, Lupu R. The angiogenic inducer CYR61 synergistically enhances Heregulin-stimulated secretion of Vascular Endothelial Growth Factor (VEGF) via αvβ3 integrin receptor: A novel therapeutic target for Small peptidomimetic αvβ3 integrin antagonists. Differentiation. 2007.
  31. Menendez JA, Oza BP, Lupu R. Fatty Acid Synthase (FAS) gene expression and FAS-catalyzed de novo fatty acid biosynthesis is necessary for estrogen-stimulated breast cancer cell proliferation and survival. Journal of Endocrinology. 2007.
  32. Menendez JA, Lupu R. Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9). Curr Pharm Biotechnol. 2006 Dec; 7(6):495-502.
    View PubMed
  33. Lupu R, Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol. 2006 Dec; 7(6):483-93.
    View PubMed
  34. Menendez JA, Vellon L, Lupu R. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. Int J Mol Med. 2006 Dec; 18(6):1081-7.
    View PubMed
  35. Menendez JA, Vazquez-Martin A, Ropero S, Colomer R, Lupu R. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". Clin Transl Oncol. 2006 Nov; 8(11):812-20.
    View PubMed
  36. Vellon L, Menendez JA, Lupu R. A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells. Mol Carcinog. 2006 Oct; 45(10):795-804.
    View PubMed
  37. Menendez JA, Papadimitropoulou A, Vellon L, Lupu R. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. Eur J Cancer. 2006 Oct; 42(15):2425-32. Epub 2006 Jan 06.
    View PubMed
  38. Lupu R, Menendez JA. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Endocrinology. 2006 Sep; 147(9):4056-66. Epub 2006 Jun 29.
    View PubMed
  39. Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol. 2006 Aug 10; 24(23):3735-46. Epub 2006 Jul 17.
    View PubMed
  40. Menendez JA, Lupu R. Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care. 2006 Jul; 9(4):346-57.
    View PubMed
  41. Menendez JA, Vellon L, Lupu R. The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int J Gynecol Cancer. 2006 Jan-Feb; 16(1):219-21.
    View PubMed
  42. Menendez JA, Lupu R. Response: Effect of -Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene. J Natl Cancer Inst. 2006; 98(10):718-20.
  43. Menendez JA, Vellon L, Colomer R, Lupu R. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene. J Natl Cancer Inst. 2005 Nov 2; 97(21):1611-5.
    View PubMed
  44. Menendez JA, Vellon L, Lupu R. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol. 2005 Aug; 16(8):1253-67. Epub 2005 May 03.
    View PubMed
  45. Menendez JA, Lupu R, Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect. 2005 Jul-Aug; 18(6):375-85.
    View PubMed
  46. Menendez JA, Lupu R, Colomer R. Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev. 2005 Jun; 14(3):263-70.
    View PubMed
  47. Menendez JA, Oza BP, Colomer R, Lupu R. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol. 2005 Jun; 26(6):1507-15.
    View PubMed
  48. Vellon L, Menendez JA, Lupu R. AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene. 2005 May 26; 24(23):3759-73.
    View PubMed
  49. Menendez JA, Vellon L, Colomer R, Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer. 2005 May 20; 115(1):19-35.
    View PubMed
  50. Menendez JA, Vellon L, Oza BP, Lupu R. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene. J Cell Biochem. 2005 Apr 1; 94(5):857-63.
    View PubMed
  51. Menendez JA, Vellon L, Lupu R. Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med (Maywood). 2005 Mar; 230: (3)151-4.
    View PubMed
  52. Menendez JA, Mehmi I, Lupu R. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Int J Oncol. 2005 Mar; 26(3):649-59.
    View PubMed
  53. Menendez JA, Vellon L, Colomer R, Lupu R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Ann Oncol. 2005 Mar; 16(3):359-71. Epub 2005 Jan 10.
    View PubMed
  54. Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, Lupu R. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene. 2005 Jan 27; 24(5):761-79.
    View PubMed
  55. Menendez JA, Vellon L, Lupu R. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses. 2005; 64(5):997-1001.
    View PubMed
  56. Menendez JA, Colomer R, Lupu R. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med Hypotheses. 2005; 64(2):342-9.
    View PubMed
  57. Menendez JA, Colomer R, Lupu R. Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis. Med Hypotheses. 2005; 64(2):337-41.
    View PubMed
  58. Menendez JA, Lupu R. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Int J Mol Med. 2005 Jan; 15(1):33-40.
    View PubMed
  59. Menendez JA, Decker JP, Lupu R. In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J Cell Biochem. 2005 Jan 1; 94(1):1-4.
    View PubMed
  60. Menendez JA, Lupu R. Fatty Acid Synthase is a novel regulator of Her-2/neu (erbB-2) oncogene in breast cancer cells. Tumor Microenvir: Progression, Therapy and Prevention.. 2005; S.r.l.: 29-41.
  61. Menendez JA, Lupu R. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz). 2004 Nov-Dec; 52: (6)414-26.
    View PubMed
  62. Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog. 2004 Nov; 41(3):164-78.
    View PubMed
  63. Menendez JA, Colomer R, Lupu R. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncol Rep. 2004 Aug; 12(2):411-22.
    View PubMed
  64. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A. 2004 Jul 20; 101(29):10715-20. Epub 2004 Jul 02.
    View PubMed
  65. Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene. 2004 Jun 17; 23(28):4945-58.
    View PubMed
  66. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol. 2004 Jun; 24(6):1369-83.
    View PubMed
  67. Menendez JA, Ropero S, Lupu R, Colomer R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncol Rep. 2004 Jun; 11(6):1241-52.
    View PubMed
  68. Menendez JA, Lupu R, Colomer R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res Treat. 2004 Mar; 84(2):183-95.
    View PubMed
  69. Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol. 2004 Mar; 24(3):591-608.
    View PubMed
  70. Menendez JA, Ropero S, Lupu R, Colomer R. ω-6 Gamma-Linolenic fatty acid Enhances Docetaxel Cytotoxic in Human Breast Cancer Cells: Relationship to lipid peroxidation and HER-2 expression. Oncology Reports. 2004; 11(6):1241-52.
  71. Lupu R, Mehmi I, Atlas E, Tsai MS, Pisha E, Oketch-Rabah HA, Nuntanakorn P, Kennelly EJ, Kronenberg F. Black cohosh, a menopausal remedy, does not have estrogenic activity and does not promote breast cancer cell growth. Int J Oncol. 2003 Nov; 23(5):1407-12.
    View PubMed
  72. Menendez JA, Mehmi I, Griggs DW, Lupu R. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer. 2003 Jun; 10(2):141-52.
    View PubMed
  73. Atlas E, Bojanowski K, Mehmi I, Lupu R. A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity. Oncogene. 2003 May 29; 22(22):3441-51.
    View PubMed
  74. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene. 2003 Feb 6; 22(5):761-8.
    View PubMed
  75. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res. 2003 Jan; 1(3):165-75.
    View PubMed
  76. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene. 2002 Nov 21; 21(53):8178-85.
    View PubMed
  77. Puricelli L, Proietti CJ, Labriola L, Salatino M, Balana ME, Aguirre Ghiso J, Lupu R, Pignataro OP, Charreau EH, Bal de Kier Joffe E, Elizalde PV. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. Int J Cancer. 2002 Aug 20; 100(6):642-53.
    View PubMed
  78. Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R. Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene. 2002 Jan 31; 21(6):964-73.
    View PubMed
  79. Guerra-Vladusic FK, Vladusic EA, Tsai MS, Lupu R. Signaling molecules implicated in heregulin induction of growth arrest and apoptosis. Oncol Rep. 2001 Nov-Dec; 8(6):1203-14.
    View PubMed
  80. Colomer R, Shamon LA, Tsai MS, Lupu R. Herceptin: from the bench to the clinic. Cancer Invest. 2001; 19(1):49-56.
    View PubMed
  81. Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AM. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene. 2000 Dec 14; 19(54):6271-6.
    View PubMed
  82. Tsai MS, Hornby AE, Lakins J, Lupu R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res. 2000 Oct 15; 60(20):5603-7.
    View PubMed
  83. Hijazi MM, Thompson EW, Tang C, Coopman P, Torri JA, Yang D, Mueller SC, Lupu R. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. Int J Oncol. 2000 Oct; 17(4):629-41.
    View PubMed
  84. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J, Lupu R. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol Rep. 2000 Jan-Feb; 7(1):157-67.
    View PubMed
  85. Liu WM, Guerra-Vladusic FK, Kurakata S, Lupu R, Kohwi-Shigematsu T. HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. Cancer Res. 1999 Nov 15; 59(22):5695-703.
    View PubMed
  86. Balana ME, Lupu R, Labriola L, Charreau EH, Elizalde PV. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. Oncogene. 1999 Nov 4; 18(46):6370-9.
    View PubMed
  87. Guerra-Vladusic FK, Scott G, Weaver V, Vladusic EA, Tsai MS, Benz CC, Lupu R. Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3. Int J Oncol. 1999 Nov; 15(5):883-92.
    View PubMed
  88. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci U S A. 1998 Dec 8; 95(25):14821-6.
    View PubMed
  89. Harris LN, Yang L, Tang C, Yang D, Lupu R. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. Clin Cancer Res. 1998 Apr; 4(4):1005-12.
    View PubMed
  90. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R. Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res. 1998 Jan 15; 58(2):210-4.
    View PubMed
  91. Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA, Pfreundschuh M, Waldmann TA, Horak ID. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. Int J Cancer. 1997 Jan 17; 70(2):221-9.
    View PubMed
  92. Saceda M, Grunt TW, Colomer R, Lippman ME, Lupu R, Martin MB. Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology. 1996 Oct; 137(10):4322-30.
    View PubMed
  93. Cardillo M, Yankelevich B, Mazumder A, Lupu R. Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells. Cancer Immunol Immunother. 1996 Sep; 43(1):19-25.
    View PubMed
  94. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res. 1996 Jul 15; 56(14):3350-8.
    View PubMed
  95. Sepp-Lorenzino L, Eberhard I, Ma Z, Cho C, Serve H, Liu F, Rosen N, Lupu R. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene. 1996 Apr 18; 12(8):1679-87.
    View PubMed
  96. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat. 1996; 38(1):57-66.
    View PubMed
  97. Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittrich C. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer. 1995 Nov 15; 63(4):560-7.
    View PubMed
  98. Lupu R, Cardillo M, Harris L, Hijazi M, Rosenberg K. Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol. 1995 Jun; 6(3):135-45.
    View PubMed
  99. Avila MA, Velasco JA, Cho C, Lupu R, Wen D, Notario V. Hyperactive autocrine loop mediated by a NDF-related factor in neoplastic hamster embryo fibroblasts expressing an activated cph oncogene. Oncogene. 1995 Mar 2; 10(5):963-71.
    View PubMed
  100. Elizalde PV, Guerra FK, Gravano M, Lanari C, Lippman ME, Charreau EH, Lupu R. Correlation of TGF-beta 1 expression with medroxyprogesterone acetate responsiveness in mouse mammary adenocarcinomas. Cancer Invest. 1995; 13(2):173-80.
    View PubMed
  101. Colomer R, Lupu R, Bacus SS, Gelmann EP. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer. 1994 Nov; 70(5):819-25.
    View PubMed
  102. Staebler A, Sommers C, Mueller SC, Byers S, Thompson EW, Lupu R. Modulation of breast cancer progression and differentiation by the gp30/heregulin [correction of neregulin]. Breast Cancer Res Treat. 1994; 31(2-3):175-82.
    View PubMed
  103. Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles E, Ben-Baruch N, Farbstein H, Lupu R, et al. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res. 1993 Nov 1; 53(21):5251-61.
    View PubMed
  104. Noguchi M, Murakami M, Bennett W, Lupu R, Hui F Jr, Harris CC, Gerwin BI. Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. Cancer Res. 1993 May 1; 53(9):2035-43.
    View PubMed
  105. Celano P, Berchtold CM, Mabry M, Carroll M, Sidransky D, Casero RA Jr, Lupu R. Induction of markers of normal differentiation in human colon carcinoma cells by the v-rasH oncogene. Cell Growth Differ. 1993 Apr; 4(4):341-7.
    View PubMed
  106. Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC Jr. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer. 1993 Feb 1; 53(3):401-8.
    View PubMed
  107. Lupu R, Lippman ME. William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat. 1993; 27(1-2):83-93.
    View PubMed
  108. Lupu R, Dickson RB, Lippman ME. The role of erbB-2 and its ligands in growth control of malignant breast epithelium. J Steroid Biochem Mol Biol. 1992 Sep; 43(1-3):229-36.
    View PubMed
  109. Lupu R, Wellstein A, Sheridan J, Ennis BW, Zugmaier G, Katz D, Lippman ME, Dickson RB. Purification and characterization of a novel growth factor from human breast cancer cells. Biochemistry. 1992 Aug 18; 31(32):7330-40.
    View PubMed
  110. Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman M, Lupu R. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ. 1992 Jul; 3(7):401-11.
    View PubMed
  111. Lupu R, Colomer R, Kannan B, Lippman ME. Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci U S A. 1992 Mar 15; 89(6):2287-91.
    View PubMed
  112. Bano M, Lupu R, Kidwell WR, Lippman ME, Dickson RB. Production and characterization of mammary-derived growth factor 1 in mammary epithelial cell lines. Biochemistry. 1992 Jan 21; 31(2):610-6.
    View PubMed
  113. Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB, Lippman M. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res. 1991 Jul 1; 51(13):3590-4.
    View PubMed
  114. Lupu R, Dickson RB, Lippman ME. The role of erbB-2 and its ligands in growth control of malignant breast epithelium. Princess Takamatsu Symp. 1991; 22:49-60.
    View PubMed
  115. Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D, Lippman ME. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science. 1990 Sep 28; 249(4976):1552-5.
    View PubMed
  116. Falco JP, Baylin SB, Lupu R, Borges M, Nelkin BD, Jasti RK, Davidson NE, Mabry M. v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line. J Clin Invest. 1990 Jun; 85(6):1740-5.
    View PubMed
  117. Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, Kern FG. Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ. 1990 Feb; 1: (2)63-71.
    View PubMed
  118. Yee D, Favoni RE, Lupu R, Cullen KJ, Lebovic GS, Huff KK, Lee PD, Lee YL, Powell DR, Dickson RB, et al. The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells. Biochem Biophys Res Commun. 1989 Jan 16; 158(1):38-44.
    View PubMed
  119. Smorodinsky NI, Argov S, Ghendles Y, Bakimer R, Krup M, Lupu R, Keydar I, Shoenfeld Y. Human monoclonal antibodies derived from pleural effusion lymphocytes of a patient with breast carcinoma react with human breast cancer-associated antigens and mouse mammary tumor virus polypeptides. Exp Cell Biol. 1987; 55(5):237-49.
    View PubMed